Eduardo Rene Salas - 30 Dec 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
Director
Signature
/s/ Eduardo Rene Salas, by Michael A. Goldstein as attorney-in-fact
Issuer symbol
ADMA
Transactions as of
30 Dec 2024
Net transactions value
$0
Form type
4
Filing time
02 Jan 2025, 16:15:30 UTC
Previous filing
25 Jun 2024
Next filing
21 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (right to buy) Award $0 +20,011 $0.000000 20,011 30 Dec 2024 Common Stock 20,011 $17.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted to the reporting person on 12/30/2024 upon joining the ADMA Biologics, Inc. Board of Directors and will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.